IRES-C11

IRES-C11 is a spectfic c-MYC internal ribosome entry site (IRES) translation inhibitor. IRES-C11 blocks the interaction of a requisite c-MYC IRES trans-acting factor, heterogeneous nuclear ribonucleoprotein A1, with its IRES. IRES-C11 does not inhibits BAG-1, XIAP and p53 IRESes[1][2].

Product Specifications

CAS Number

[342416-30-2]

UNSPSC

12352005

Hazard Statement

H302+H312+H332

Target

C-Myc

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ires-c11.html

Purity

98.01

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(C(Cl)=C1Cl)N(CC2=CC=C(OC)C=C2OC)C1=O

Molecular Formula

C13H11Cl2NO4

Molecular Weight

316.14

Precautions

H302+H312+H332

References & Citations

[1]Brent Holmes, et al. Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES) -mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma. J Biol Chem. 2016 Jul 1;291 (27) :14146-14159.|[2]Y Shi, et al. Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress. Oncogene. 2016 Feb 25;35 (8) :1015-24.